Telix Pharmaceuticals (TLX) Stock Price, News & Analysis

Company Overview

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

Key Stats

• Today's Range: $11.70 to $12.00
• 50-Day Range: $11.78 to $17.48
• 52-Week Range: $11.70 to $30.36
• Volume: 31,511 shs
• Average Volume: 64,590 shs
• Market Capitalization: $3.99 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $22.33
• Consensus Rating: Buy

TLX Stock Analysis - Frequently Asked Questions

How have TLX shares performed this year?

Telix Pharmaceuticals' stock was trading at $15.40 at the beginning of 2025. Since then, TLX stock has decreased by 23.5% and is now trading at $11.78.

When did Telix Pharmaceuticals IPO?

Telix Pharmaceuticals (TLX) raised $202 million in an initial public offering on Friday, June 14th 2024. The company issued 17,000,000 shares at a price of $11.87 per share.

Who are Telix Pharmaceuticals' major shareholders?

Telix Pharmaceuticals' top institutional shareholders include Pier Capital LLC (0.06%), Vanguard Personalized Indexing Management LLC (0.01%) and Blair William & Co. IL.

How do I buy shares of Telix Pharmaceuticals?

Shares of TLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 8/07/2025
• Next Earnings (Estimated): 8/20/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TLX
• Previous Symbol: NASDAQ:TLX
• CIK: 2007191
• Web: www.telixpharma.com
• Phone: 61-3-9093-3855
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Telix Pharmaceuticals: $22.33
• High Price Target: $23.00
• Low Price Target: $22.00
• Potential Upside/Downside: +89.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.99
• Current Ratio: 2.78
• Quick Ratio: 2.66

Sales & Book Value

• Annual Sales: $516.72 million
• Price / Sales: 7.71
• Cash Flow: $0.11 per share
• Price / Cash Flow: 107.36
• Book Value: $1.12 per share
• Price / Book: 10.52

Miscellaneous

• Outstanding Shares: 338,400,000
• Free Float: N/A
• Market Cap: $3.99 billion
• Optionable: N/A
• Beta: N/A